BVXP Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Bioventix (LON: BVXP)
›
Bioventix (LON: BVXP) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 1950.00 GBp on 19 November 2026, down 10.3% over 52 weeks.
At a market capitalisation of 101.88M GBP, it trades at 13.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 60% for BVXP. It pays a dividend yielding 7.69% (it pays out 104% of its earnings), against a median of 0.94% among the dividend payers in that peer group.
Bioventix reports return on equity of 65.7%, an operating margin of 77.3% and revenue up 6.7% year over year.
It holds more cash than debt, a net cash position of 5.25M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 3900.00 GBp is 100.0% above the current price.